Condition
28 Day Mortality
Total Trials
2
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
1Total
Not Applicable (1)
Trial Status
Unknown2
Clinical Trials (2)
Showing 2 of 2 trials
NCT05126537UnknownPrimary
Co-inhibitory Molecules on Treg and miR-155-5p in Patients With Sepsis
NCT04747106Not ApplicableUnknownPrimary
Thromboelastography Guides a Multicentre Cluster Controlled Study of Plasma Exchange for Hepatitis B Associated Acute-on-chronic Liver Failure
Showing all 2 trials